Edwards Lifesciences Corporation Edwards Lifesciences Corporation

Edwards Lifesciences Corporation

EW

株式のランク #482
Edwards Lifesciences Corporation is a global medical technology firm... Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
株価
$87.29
最終同期: 2026-10-19
時価総額
$50.31B
変化(1日)
0.96%
変化(1年)
15.94%
国
US
取引 Edwards Lifesciences Corporation (EW)

カテゴリー

Healthcare
Edwards Lifesciences Corporation(EW)の利益
Jun 2026 時点の利益 TTM: $1.42B
Edwards Lifesciences Corporation の最新の財務報告によると、同社の現在の利益は $1.42B です。2024 年には $1.55B の利益を上げ、これは 2023 年の利益 $1.37B と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Edwards Lifesciences Corporation の利益の推移(2000 〜 2026)
各年末の利益
年 利益 変化
2026 (TTM) $1.42B 11.37%
2025 $1.27B -17.78%
2024 $1.55B 12.80%
2023 $1.37B -22.35%
2022 $1.77B 3.84%
2021 $1.70B 85.67%
2020 $916.70M -21.41%
2019 $1.17B 53.20%
2018 $761.40M -26.43%
2017 $1.03B 40.25%
2016 $737.90M 18.56%
2015 $622.40M -45.59%
2014 $1.14B 122.01%
2013 $515.30M 31.76%
2012 $391.10M 37.91%
2011 $283.60M 5.74%
2010 $268.20M -11.89%
2009 $304.40M 85.16%
2008 $164.40M 9.75%
2007 $149.80M -13.06%
2006 $172.30M 47.64%
2005 $116.70M 287.71%
2004 $30.10M -67.56%
2003 $92.80M 65.71%
2002 $56.00M -722.22%
2001 $-9.00M -96.53%
2000 $-259.00M 0.00%
同業他社の利益
企業 利益 利益の差 国
$7.51B 429.84%
US
$5.56B 292.42%
IE
$5.15B 263.15%
US
$3.86B 172.36%
US
- -
DE